For non-small cell lung cancer (NSCLC) patients, advancements in medical technology have uniquely positioned laboratory benefit managers to assist health plans in increasing the quality of care, enable providers to utilize broad panel genomic testing and incorporate liquid biomarker testing, and eliminate PA bottlenecks.?? ? In this article, Avalon Vice President of Product Matt Ingram and Avalon Product Manager Dr. Michael Dovidio, PharmD, explore how effective laboratory value management and non-invasive liquid biomarker testing can transform patient care by accelerating patient identification, reducing the need for tissue samples, and minimizing costs.?? ? Read More: https://lnkd.in/gvuVxk2b??? ? #AvalonHCS #Oncology #CancerTreatment #LaboratoryBenefitManagement??
